Top

Current Allergy and Asthma Reports

Published in:

31-05-2023 | Sarcoidosis

Neurosarcoidosis: Diagnostic Challenges and Mimics A Review

Authors: Jeffrey Shen, Elijah Lackey, Suma Shah

Published in: Current Allergy and Asthma Reports | Issue 7/2023

Abstract

Purpose of Review

Neurosarcoidosis is a rare manifestation of sarcoidosis that is challenging to diagnose. Biopsy confirmation of granulomas is not sufficient, as other granulomatous diseases can present similarly. This review is intended to guide the clinician in identifying key conditions to exclude prior to concluding a diagnosis of neurosarcoidosis.

Recent Findings

Although new biomarkers are being studied, there are no reliable tests for neurosarcoidosis. Advances in serum testing and imaging have improved the diagnosis for key mimics of neurosarcoidosis in certain clinical scenarios, but biopsy remains an important method of differentiation.

Summary

Key mimics of neurosarcoidosis in all cases include infections (tuberculosis, fungal), autoimmune disease (vasculitis, IgG4-related disease), and lymphoma. As neurosarcoidosis can affect any part of the nervous system, patients should have a unique differential diagnosis tailored to their clinical presentation. Although biopsy can assist with excluding mimics, diagnosis is ultimately clinical.

•• Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220. https://doi.org/10.1186/s12883-016-0741-x. This is the largest meta-analysis of neurosarcoidosis patients to date.CrossRefPubMedPubMedCentral

•• Barreras P, Stern BJ. Clinical features and diagnosis of neurosarcoidosis - review article. J Neuroimmunol. 2022;368:577871. https://doi.org/10.1016/j.jneuroim.2022.577871. This is the most recent, comprehensive review providing diagnostic algorithms for clinicians to use when evaluating patients with suspected neurosarcoidosis.

Kidd DP. Neurosarcoidosis: clinical manifestations, investigation and treatment. Pract Neurol. 2020;20(3):199–212. https://doi.org/10.1136/practneurol-2019-002349.CrossRefPubMed

Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. Neurol Neuroimmunol Neuroinflamm. 2021;8(6). https://doi.org/10.1212/nxi.0000000000001084.

Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis–diagnosis and management. QJM. 1999;92(2):103–17. https://doi.org/10.1093/qjmed/92.2.103.CrossRefPubMed

• Stern BJ, Royal W III, Gelfand JM, Clifford DB, Tavee J, Pawate S, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–53. https://doi.org/10.1001/jamaneurol.2018.2295. This is the most updated diagnostic criteria for neurosarcoidosis.CrossRefPubMed

• Baldwin KJ, Avila JD. Diagnostic approach to chronic meningitis. Neurol Clin. 2018;36(4):831–49. https://doi.org/10.1016/j.ncl.2018.06.004. This resource will help the clinician navigate the differential of a patient presenting with chronic meningitis from suspected neurosarcoidosis.CrossRefPubMed

Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001;248(5):363–72. https://doi.org/10.1007/s004150170175.CrossRefPubMed

• Challa S. Granulomatous diseases of the central nervous system: approach to diagnosis. Indian J Pathol Microbiol. 2022;65(Supplement):S125–34. https://doi.org/10.4103/ijpm.ijpm_1067_21. This resource will help the clinician navigate the differential of a patient with granulomas on biopsy.CrossRefPubMed

10.

Zumla A, James DG. Granulomatous infections: etiology and classification. Clin Infect Dis. 1996;23(1):146–58. https://doi.org/10.1093/clinids/23.1.146.CrossRefPubMed

11.

Furin J, Cox H, Pai M. Tuberculosis Lancet. 2019;393(10181):1642–56. https://doi.org/10.1016/s0140-6736(19)30308-3.CrossRefPubMed

12.

• Dian S, Ganiem AR, van Laarhoven A. Central nervous system tuberculosis. Curr Opin Neurol. 2021;34(3):396–402. https://doi.org/10.1097/wco.0000000000000920. This resource will help the clinician exclude TB prior to diagnosing neurosarcoidosis.CrossRefPubMedPubMedCentral

13.

•• Nwebube CO, Bou GA, Castilho AJ, Hutto SK. Facial nerve palsy in neurosarcoidosis: clinical course, neuroinflammatory accompaniments, ancillary investigations, and response to treatment. J Neurol. 2022;269(10):5328–36. https://doi.org/10.1007/s00415-022-11189-6. This is the largest and most recent cohort for patients with facial palsy from neurosarcoidosis.CrossRefPubMed

14.

Ramos-Casals M, Pérez-Alvarez R, Kostov B, Gómez-de-la-Torre R, Feijoo-Massó C, Chara-Cervantes J, et al. Clinical characterization and outcomes of 85 patients with neurosarcoidosis. Sci Rep. 2021;11(1):13735. https://doi.org/10.1038/s41598-021-92967-6.CrossRefPubMedPubMedCentral

15.

Arun T, Pattison L, Palace J. Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: a retrospective study. Neurology. 2020;94(24):e2545–54. https://doi.org/10.1212/wnl.0000000000009491.CrossRefPubMed

16.

Leonard JM. Central nervous system tuberculosis. Microbiol Spectr. 2017;5(2). https://doi.org/10.1128/microbiolspec.TNMI7-0044-2017.

17.

Pehlivanoglu F, Yasar KK, Sengoz G. Tuberculous meningitis in adults: a review of 160 cases. ScientificWorldJournal. 2012;2012:169028. https://doi.org/10.1100/2012/169028.

18.

Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2003;3(10):633–43. https://doi.org/10.1016/s1473-3099(03)00772-2.CrossRefPubMed

19.

Siddiqi OK, Birbeck GL, Ghebremichael M, Mubanga E, Love S, Buback C, et al. Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF lipoarabinomannan (LAM) lateral flow assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia. J Clin Microbiol. 2019;57(8). https://doi.org/10.1128/jcm.00652-19.

20.

Wen A, Leng EL, Liu SM, Zhou YL, Cao WF, Yao DY, et al. Diagnostic accuracy of interferon-gamma release assays for tuberculous meningitis: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2022;12:788692. https://doi.org/10.3389/fcimb.2022.788692.

21.

Abbasi F, Ozer M, Juneja K, Goksu SY, Mobarekah BJ, Whitman MS. Intracranial tuberculoma mimicking neurosarcoidosis: a clinical challenge. Infect Dis Rep. 2021;13(1):181–6. https://doi.org/10.3390/idr13010020.CrossRefPubMedPubMedCentral

22.

Jarman PR. Meningeal granulomas: sarcoidosis or tuberculosis? Differentiation can be difficult Bmj. 1995;310(6978):517–20. https://doi.org/10.1136/bmj.310.6978.517.CrossRefPubMed

23.

Regmi BU, Pathak BD, Subedi RC, Dhakal B, Sapkota S, Joshi S, et al. Neuro-cryptococcosis in an immunocompetent individual with radiologically atypical findings: a case report and review of literature. Oxf Med Case Reports. 2023;2023(3):omad016. https://doi.org/10.1093/omcr/omad016.

24.

Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses. 2009;52(3):206–22. https://doi.org/10.1111/j.1439-0507.2008.01642.x.CrossRefPubMed

25.

Parikh SL, Venkatraman G, DelGaudio JM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol. 2004;18(2):75–81.CrossRefPubMed

26.

Lang R, Stokes W, Lemaire J, Johnson A, Conly J. A case report of Coccidioides posadasii meningoencephalitis in an immunocompetent host. BMC Infect Dis. 2019;19(1):722. https://doi.org/10.1186/s12879-019-4329-0.CrossRefPubMedPubMedCentral

27.

Gottfredsson M, Perfect JR. Fungal meningitis. Semin Neurol. 2000;20(3):307–22. https://doi.org/10.1055/s-2000-9394.CrossRefPubMed

28.

Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–45. https://doi.org/10.1128/cmr.00056-10.CrossRefPubMedPubMedCentral

29.

Chen S, Chen X, Zhang Z, Quan L, Kuang S, Luo X. MRI findings of cerebral cryptococcosis in immunocompetent patients. J Med Imaging Radiat Oncol. 2011;55(1):52–7. https://doi.org/10.1111/j.1754-9485.2010.02229.x.CrossRefPubMed

30.

Williams DA, Kiiza T, Kwizera R, Kiggundu R, Velamakanni S, Meya DB, et al. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. Clin Infect Dis. 2015;61(3):464–7. https://doi.org/10.1093/cid/civ263.CrossRefPubMedPubMedCentral

31.

Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal meningitis diagnostics and screening in the era of point-of-care laboratory testing. J Clin Microbiol. 2019;57(1). https://doi.org/10.1128/jcm.01238-18.

32.

• Ten Dam L, van de Beek D, Brouwer MC. Clinical characteristics and outcome of hydrocephalus in neurosarcoidosis: a retrospective cohort study and review of the literature. J Neurol. 2022;269(5):2727–33. https://doi.org/10.1007/s00415-021-10882-2. This is the largest and most recent cohort for patients with hydrocephalus from neurosarcoidosis.CrossRefPubMed

33.

• Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019;21(3):296–305. https://doi.org/10.1093/neuonc/noy192. This resource will help the clinician evaluate for PCNSL prior to diagnosing neurosarcoidosis.CrossRefPubMed

34.

Joshi A, Deshpande S, Bayaskar M. Primary CNS lymphoma in Immunocompetent patients: appearances on conventional and advanced imaging with review of literature. J Radiol Case Rep. 2022;16(7):1–17. https://doi.org/10.3941/jrcr.v16i7.4562.CrossRefPubMedPubMedCentral

35.

• Carlson ML, White JR Jr, Espahbodi M, Haynes DS, Driscoll CL, Aksamit AJ, et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients. Otol Neurotol. 2015;36(1):156–66. https://doi.org/10.1097/mao.0000000000000501. This is the most recent and largest review on skull base neurosarcoidosis which has its own differential diagnosis.CrossRefPubMed

36.

•• Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol. 2013;70(3):311–9. https://doi.org/10.1001/jamaneurol.2013.606. This is the most recent review on diagnosing CNS lymphoma both primary and secondary.CrossRefPubMedPubMedCentral

37.

Feldman L, Li Y, Ontaneda D. Primary CNS lymphoma initially diagnosed as vasculitis. Neurol Clin Pract. 2020;10(1):84–8. https://doi.org/10.1212/cpj.0000000000000693.CrossRefPubMedPubMedCentral

38.

•• Saygin D, Jones S, Sundaram P, Calabrese LH, Messner W, Tavee JO, et al. Differentiation between neurosarcoidosis and primary central nervous system vasculitis based on demographic, cerebrospinal and imaging features. Clin Exp Rheumatol. 2020;38 Suppl 124(2):135–8. This resource will help the clinician differentiate PACNS from neurosarcoidosis.

39.

Maekawa T, Goto Y, Aoki T, Hino A, Oka H, Yokoya S, et al. Acute central nervous system vasculitis as a manifestation of neurosarcoidosis: a case report and literature review. Radiol Case Rep. 2021;16(2):410–4. https://doi.org/10.1016/j.radcr.2020.11.047.CrossRefPubMed

40.

• Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. https://doi.org/10.1002/art.37715. This is the most updated list of different causes of vasculitis, a common mimic of neurosarcoidosis.CrossRefPubMed

41.

Boulouis G, de Boysson H, Zuber M, Guillevin L, Meary E, Costalat V, et al. Primary angiitis of the central nervous system: magnetic resonance imaging spectrum of parenchymal, meningeal, and vascular lesions at baseline. Stroke. 2017;48(5):1248–55. https://doi.org/10.1161/strokeaha.116.016194.CrossRefPubMed

42.

Bajaj BK, Pandey S, Ramanujam B, Wadhwa A. Primary angiitis of central nervous system: the story of a great masquerader. J Neurosci Rural Pract. 2015;6(3):399–401. https://doi.org/10.4103/0976-3147.158781.CrossRefPubMedPubMedCentral

43.

Zheng Y, Zhang Y, Cai M, Lai N, Chen Z, Ding M. Central nervous system involvement in ANCA-associated vasculitis: what neurologists need to know. Front Neurol. 2018;9:1166. https://doi.org/10.3389/fneur.2018.01166.CrossRefPubMed

44.

•• Kandemirli SG, Bathla G. Neuroimaging findings in rheumatologic disorders. J Neurol Sci. 2021;427:117531. https://doi.org/10.1016/j.jns.2021.117531. This resource will help the clinician exclude autoimmune mimics on neuroimaging.

45.

Villa E, Sarquis T, de Grazia J, Núñez R, Alarcón P, Villegas R, et al. Rheumatoid meningitis: a systematic review and meta-analysis. Eur J Neurol. 2021;28(9):3201–10. https://doi.org/10.1111/ene.14904.CrossRefPubMed

46.

Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford). 2020;59(Suppl 3):iii123-iii31. https://doi.org/10.1093/rheumatology/kez667.

47.

•• Saitakis G, Chwalisz BK. The neurology of IGG4-related disease. J Neurol Sci. 2021;424:117420. https://doi.org/10.1016/j.jns.2021.117420. This is the most updated review on CNS IgG4-RD, and will help the clinican exclude this mimic.

48.

Woo PYM, Ng BCF, Wong JHM, Ng OKS, Chan TSK, Kwok NF, et al. The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases. Chin Neurosurg J. 2021;7(1):13. https://doi.org/10.1186/s41016-021-00233-5.CrossRefPubMedPubMedCentral

49.

Amirbaigloo A, Esfahanian F, Mouodi M, Rakhshani N, Zeinalizadeh M. IgG4-related hypophysitis. Endocrine. 2021;73(2):270–91. https://doi.org/10.1007/s12020-021-02714-0.CrossRefPubMed

50.

Baptista B, Casian A, Gunawardena H, D’Cruz D, Rice CM. Neurological manifestations of IgG4-related disease. Curr Treat Options Neurol. 2017;19(4):14. https://doi.org/10.1007/s11940-017-0450-9.CrossRefPubMedPubMedCentral

51.

Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92. https://doi.org/10.1038/modpathol.2012.72.CrossRefPubMed

52.

• Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77–87. https://doi.org/10.1136/annrheumdis-2019-216561. This is the most updated criteria for diagnosing IgG4-RD.CrossRefPubMed

53.

Miller BH, Rosado-de-Christenson ML, McAdams HP, Fishback NF. Thoracic sarcoidosis: radiologic-pathologic correlation. Radiographics. 1995;15(2):421–37. https://doi.org/10.1148/radiographics.15.2.7761646.CrossRefPubMed

54.

Armstrong P, Wilson AG, Dee P, Hansell DM. Imaging of diseases of the chest. vol Ed. 3. Mosby International Ltd; 2000.

55.

Nemec SF, Bankier AA, Eisenberg RL. Upper lobe-predominant diseases of the lung. AJR Am J Roentgenol. 2013;200(3):W222–37. https://doi.org/10.2214/ajr.12.8961.CrossRefPubMed

56.

Ma SP, Rogers SL, Hall AJ, Hodgson L, Brennan J, Stawell RJ, et al. Sarcoidosis-related uveitis: clinical presentation, disease course, and rates of systemic disease progression after uveitis diagnosis. Am J Ophthalmol. 2019;198:30–6. https://doi.org/10.1016/j.ajo.2018.09.013.CrossRefPubMed

57.

Pasadhika S, Rosenbaum JT. Ocular sarcoidosis. Clin Chest Med. 2015;36(4):669–83. https://doi.org/10.1016/j.ccm.2015.08.009.CrossRefPubMedPubMedCentral

58.

Serup J. How to diagnose and classify tattoo complications in the clinic: a system of distinctive patterns. Curr Probl Dermatol. 2017;52:58–73. https://doi.org/10.1159/000450780.CrossRefPubMed

59.

Redissi A, Penmetsa GK, Litaiem N. Lupus pernio. StatPearls. Treasure Island (FL): StatPearls Publishing.

60.

Popatia S, Wanat KA. Lupus pernio JAMA Dermatol. 2022;158(4):446. https://doi.org/10.1001/jamadermatol.2021.6007.CrossRefPubMed

61.

Ibitoye RT, Wilkins A, Scolding NJ. Neurosarcoidosis: a clinical approach to diagnosis and management. J Neurol. 2017;264(5):1023–8. https://doi.org/10.1007/s00415-016-8336-4.CrossRefPubMed

62.

Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17. https://doi.org/10.1001/archneur.1985.04060080095022.CrossRefPubMed

63.

James DG, Sharma OP. Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):27–32.PubMed

64.

Makimoto G, Kawakado K, Nakanishi M, Tamura T, Noda M, Makimoto S, et al. Heerfordt’s syndrome associated with trigeminal nerve palsy and reversed halo sign. Intern Med. 2021;60(11):1747–52. https://doi.org/10.2169/internalmedicine.6176-20.CrossRefPubMed

65.

•• Kidd DP, Burton BJ, Graham EM, Plant GT. Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e270. https://doi.org/10.1212/nxi.0000000000000270. This is the most updated and largest study on patients with optic neuropathy from sarcoidosis

66.

Rothova A, Ooijman F, Kerkhoff F, Van Der Lelij A, Lokhorst HM. Uveitis masquerade syndromes. Ophthalmology. 2001;108(2):386–99. https://doi.org/10.1016/s0161-6420(00)00499-1.CrossRefPubMed

67.

• Ronquillo Y, Patel BC. Nonspecific orbital inflammation. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC. 2023. This resource provides a differential diagnosis for orbital pseudotumor.

68.

Thouvenot E, Mura F, De Verdal M, Carlander B, Charif M, Schneider C, et al. Ipsilateral uveitis and optic neuritis in multiple sclerosis. Mult Scler Int. 2012;2012:372361. https://doi.org/10.1155/2012/372361.

69.

Casselman P, Cassiman C, Casteels I, Schauwvlieghe PP. Insights into multiple sclerosis-associated uveitis: a scoping review. Acta Ophthalmol. 2021;99(6):592–603. https://doi.org/10.1111/aos.14697.

70.

Chan F, Riminton DS, Ramanathan S, Reddel SW, Hardy TA. Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to “overlap” cases. J Neuroimmunol. 2022;369:577904. https://doi.org/10.1016/j.jneuroim.2022.577904.

71.

Davis EJ, Rathinam SR, Okada AA, Tow SL, Petrushkin H, Graham EM, et al. Clinical spectrum of tuberculous optic neuropathy. J Ophthalmic Inflamm Infect. 2012;2(4):183–9. https://doi.org/10.1007/s12348-012-0079-5.CrossRefPubMedPubMedCentral

72.

Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord. 2017;14:72–9. https://doi.org/10.1016/j.msard.2017.04.003.CrossRefPubMed

73.

Pichi F, Invernizzi A, Tucker WR, Munk MR. Optical coherence tomography diagnostic signs in posterior uveitis. Prog Retin Eye Res. 2020;75:100797. https://doi.org/10.1016/j.preteyeres.2019.100797.

74.

Eckstein C, Saidha S, Sotirchos ES, Byraiah G, Seigo M, Stankiewicz A, et al. Detection of clinical and subclinical retinal abnormalities in neurosarcoidosis with optical coherence tomography. J Neurol. 2012;259(7):1390–8. https://doi.org/10.1007/s00415-011-6363-8.CrossRefPubMed

75.

Keane JR. Multiple cranial nerve palsies: analysis of 979 cases. Arch Neurol. 2005;62(11):1714–7. https://doi.org/10.1001/archneur.62.11.1714.CrossRefPubMed

76.

• Mehta MM, Garg RK, Rizvi I, Verma R, Goel MM, Malhotra HS, et al. The multiple cranial nerve palsies: a prospective observational study. Neurol India. 2020;68(3):630–5. https://doi.org/10.4103/0028-3886.289003. This is the most recent, and second largest study on patients with multiple cranial nerve palsies.CrossRefPubMed

77.

Perzyńska-Mazan J, Maślińska M, Gasik R. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018;56(2):99–105. https://doi.org/10.5114/reum.2018.75521.CrossRefPubMedPubMedCentral

78.

Yokoseki A, Saji E, Arakawa M, Kosaka T, Hokari M, Toyoshima Y, et al. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain. 2014;137(Pt 2):520–36. https://doi.org/10.1093/brain/awt314.CrossRefPubMed

79.

• Lee B, Bae YJ, Choi BS, Choi BY, Cho SJ, Kim H, et al. Radiologic differentiation between granulomatosis with polyangiitis and its mimics involving the skull base in humans using high-resolution magnetic resonance imaging. Diagnostics (Basel). 2021;11(11). https://doi.org/10.3390/diagnostics11112162. This resource will guide the clinician evaluate the differential diagnosis of skull base inflammation.

80.

Park BJ, Ray E, Bathla G, Bruch LA, Streit JA, Cho TA, et al. Single center experience with isolated spinal cord neurosarcoidosis. World Neurosurg. 2021;156:e398–407. https://doi.org/10.1016/j.wneu.2021.09.089.CrossRefPubMed

81.

Sakushima K, Yabe I, Nakano F, Yoshida K, Tajima Y, Houzen H, et al. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol. 2011;258(12):2163–7. https://doi.org/10.1007/s00415-011-6080-3.CrossRefPubMed

82.

Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. 2014;347(3):195–8. https://doi.org/10.1097/MAJ.0b013e3182808781.CrossRefPubMed

83.

Soni N, Bathla G, Pillenahalli MR. Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature. Neuroradiol J. 2019;32(1):17–28. https://doi.org/10.1177/1971400918806634.CrossRefPubMed

84.

• Murphy OC, Salazar-Camelo A, Jimenez JA, Barreras P, Reyes MI, Garcia MA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurology - Neuroimmunology Neuroinflammation. 2020;7(4):e722. https://doi.org/10.1212/nxi.0000000000000722. This is the most recent study on sarcoid myelopathy.

85.

Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol. 2014;27(3):279–89. https://doi.org/10.1097/wco.0000000000000093.CrossRefPubMed

86.

Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016;79(3):437–47. https://doi.org/10.1002/ana.24582.CrossRefPubMed

87.

Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, et al. Area postrema syndrome. Neurology. 2018;91(17):e1642. https://doi.org/10.1212/WNL.0000000000006392.

88.

Gombolay GY, Gadde JA. Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: a review. J Neuroimmunol. 2021;358:577653. https://doi.org/10.1016/j.jneuroim.2021.577653.

89.

Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268–82. https://doi.org/10.1016/S1474-4422(22)00431-8.CrossRefPubMed

90.

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016;15(4):391–404. https://doi.org/10.1016/s1474-4422(15)00401-9.CrossRefPubMedPubMedCentral

91.

Kidd DP. Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results. J Neurol. 2018;265(8):1906–15. https://doi.org/10.1007/s00415-018-8928-2.CrossRefPubMed

92.

Wallace ZS, Carruthers MN, Khosroshahi A, Carruthers R, Shinagare S, Stemmer-Rachamimov A, et al. IgG4-related disease and hypertrophic pachymeningitis. Medicine (Baltimore). 2013;92(4):206–16. https://doi.org/10.1097/MD.0b013e31829cce35.CrossRefPubMed

93.

Kupersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ. Idiopathic hypertrophic pachymeningitis. Neurology. 2004;62(5):686–94. https://doi.org/10.1212/01.wnl.0000113748.53023.b7.CrossRefPubMed

94.

Mekinian A, Maisonobe L, Boukari L, Melenotte C, Terrier B, Ayrignac X, et al. Characteristics, outcome and treatments with cranial pachymeningitis: a multicenter French retrospective study of 60 patients. Medicine (Baltimore). 2018;97(30):e11413. https://doi.org/10.1097/MD.0000000000011413.

95.

Jachiet V, Lhote R, Rufat P, Pha M, Haroche J, Crozier S, et al. Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis. J Neurol. 2018;265(10):2333–41. https://doi.org/10.1007/s00415-018-9001-x.CrossRefPubMed

96.

Veres L, Utz JP, Houser OW. Sarcoidosis presenting as a central nervous system mass lesion. Chest. 1997;111(2):518–21. https://doi.org/10.1378/chest.111.2.518.CrossRefPubMed

97.

Shah R, Roberson GH, Cure JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol. 2009;30(5):953–61. https://doi.org/10.3174/ajnr.A1470.CrossRefPubMedPubMedCentral

98.

Scott TF. Neurosarcoidosis mimicry of MS: clues from cases with CNS tissue diagnosis. J Neurol Sci. 2021;429:117621. https://doi.org/10.1016/j.jns.2021.117621.

99.

Eurelings LEM, Miedema JR, Dalm V, van Daele PLA, van Hagen PM, van Laar JAM, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One. 2019;14(10):e0223897. https://doi.org/10.1371/journal.pone.0223897.

100.

Paley MA, Baker BJ, Dunham SR, Linskey N, Cantoni C, Lee K, et al. The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells. J Neuroimmunol. 2022;367:577860. https://doi.org/10.1016/j.jneuroim.2022.577860.

101.

Khoury J, Wellik KE, Demaerschalk BM, Wingerchuk DM. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist. 2009;15(2):108–11. https://doi.org/10.1097/NRL.0b013e31819bcf84.CrossRefPubMed

102.

Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol. 2015;285:1–3. https://doi.org/10.1016/j.jneuroim.2015.05.020.CrossRefPubMed

103.

Fujisawa M, Koga M, Sato R, Oishi M, Takeshita Y, Kanda T. Spinal cord sarcoidosis in Japan: utility of cerebrospinal fluid examination and nerve conduction study for diagnosis and prognosis prediction. J Neurol. 2022;269(9):4783–90. https://doi.org/10.1007/s00415-022-11113-y.CrossRefPubMed

104.

Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis Nat Rev Dis Primers. 2019;5(1):45. https://doi.org/10.1038/s41572-019-0096-x.CrossRefPubMed

105.

Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med. 2016;22(5):484–91. https://doi.org/10.1097/mcp.0000000000000301.CrossRefPubMedPubMedCentral

106.

Deng P, Krasnozhen-Ratush O, William C, Howard J. Concurrent LETM and nerve root enhancement in spinal neurosarcoid: a case series. Mult Scler. 2018;24(14):1913–6. https://doi.org/10.1177/1352458518771518.CrossRefPubMed

107.

Bathla G, Singh AK, Policeni B, Agarwal A, Case B. Imaging of neurosarcoidosis: common, uncommon, and rare. Clin Radiol. 2016;71(1):96–106. https://doi.org/10.1016/j.crad.2015.09.007.CrossRefPubMed

108.

Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci. 2011;1:15. https://doi.org/10.4103/2156-7514.76693.CrossRefPubMedPubMedCentral

109.

•• Wahed LA, Cho TA. Imaging of central nervous system autoimmune, paraneoplastic, and neuro-rheumatologic disorders. Continuum (Minneap Minn). 2023;29(1):255–91. https://doi.org/10.1212/CON.0000000000001244. This is the most recent review on neuroimaging findings in rheumatologic disorders.CrossRefPubMed

110.

Zalewski NL, Krecke KN, Weinshenker BG, Aksamit AJ, Conway BL, McKeon A, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87(7):743–4. https://doi.org/10.1212/WNL.0000000000002992.CrossRefPubMed

111.

Bathla G, Watal P, Gupta S, Nagpal P, Mohan S, Moritani T. Cerebrovascular manifestations of neurosarcoidosis: an underrecognized aspect of the imaging spectrum. AJNR Am J Neuroradiol. 2018;39(7):1194–200. https://doi.org/10.3174/ajnr.A5492.CrossRefPubMedPubMedCentral

112.

Bathla G, Abdel-Wahed L, Agarwal A, Cho TA, Gupta S, Jones KA, et al. Vascular involvement in neurosarcoidosis: early experiences from intracranial vessel wall imaging. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1063. https://doi.org/10.1212/NXI.0000000000001063.

113.

Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, et al. Multiple sclerosis and sarcoidosis: a case for coexistence. Neurol Clin Pract. 2019;9(3):218–27. https://doi.org/10.1212/CPJ.0000000000000629.CrossRefPubMedPubMedCentral

Title: Neurosarcoidosis: Diagnostic Challenges and Mimics A Review
Authors: Jeffrey Shen
Elijah Lackey
Suma Shah
Publication date: 31-05-2023
Publisher: Springer US
Keywords: Sarcoidosis
Sarcoidosis
Vasculitis
Vasculitis
Meningitis
Lymphoma
Tuberculosis
Tuberculosis
Granulomatosis with Polyangiitis
Granulomatosis with Polyangiitis
Published in: Current Allergy and Asthma Reports / Issue 7/2023
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-023-01092-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neurosarcoidosis: Diagnostic Challenges and Mimics A Review

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2023

The Effects of Wildfire Smoke on Asthma and Allergy

Use of the Electronic Health Record for Monitoring Adverse Drug Reactions

Pathophysiological Link Between Chronic Rhinosinusitis and Ear Disease

Online Education in Allergy and Immunology: An Update to Conferences Online in Allergy (COLA)

The Relationship of Parasite Allergens to Allergic Diseases